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Abstract 
 Improved vaccines are necessary to prevent swine 
influenza, especially in young growing pigs. The objective 
of this study is to determine whether intranasal vaccination 
with Alphavirus replicon particle (RP) vector vaccine 
prevents influenza A virus (IAV) in pigs. RP vaccine was 
prepared with the hemagglutinin (HA) gene of 
pandemic H1N1 influenza virus (A/California/04/2009, 
pH1N1).  The efficacy of intranasal (IN) administration with 
pH1N1 HA RP was evaluated in two pig experiments. In the 
first experiment, prime/boost RP vaccination was 
administered IN/IN to pigs. In the second experiment, pigs 
were administered a one dose intramuscular (IM) or IN HA 
RP vaccine, or with a combination of IN/IM routes with an 
interval of three weeks. Results showed that two doses IN 
administration of HA RP did not protect pigs against IAV; 
one dose IM and combination IN/IM routes vaccination 
with HA RP reduced pneumonia significantly and partially 
inhibited virus shedding following homologous challenge. 
 
Introduction 
 A major problem of vaccinating pigs with IAV vaccine 
is that maternal antibodies interfere with the vaccine 
efficacy. Mucosal vaccination has the potential to avoid 
maternal antibodies interfering with vaccine efficacy in 
piglets. Previous studies indicated that IN administrated 
vaccine could induce immune response and protect pigs. 
The objective of this study is to determine if intranasal 
vaccination with RP vector vaccine prevents IAV in pigs. 
 
 
Methods and Materials 
RP vaccine: RP vaccine was prepared with the HA gene of 
pH1N1. 
Experiment 1: Fifteen IAV maternal antibody free pigs were 
vaccinated with RP. Prime/boost RP vaccination was 
administered IN/IN to pigs, with IM/IM administration as 
positive control and sham vaccination as negative control 
(five pigs each group) (Table 1). Three weeks post boost 
vaccination, all pigs were challenged by homologous virus. 
Experiment 2: Twenty-five IAV antibody free pigs were 
involved. Five pigs in each group were administered with 
one dose HA RP vaccine IM or IN, or with a combination of 
IN/IM routes with an interval of three weeks (Table 2). 
Positive control and negative control groups received the 
same vaccination treatment as experiment 1. All pigs were 
challenged by homologous challenge following two doses 
vaccination. 
Assays and observation: All pigs were killed and necropsied 
on the fifth day post challenge. Anti-HA antibody titer in 
serum was tested by Hemagglutination-inhibition (HI) test. 
Live virus was isolated from nasal swab and 
bronchoalveolar lavage (BAL) samples. Clinical signs 
including body temperatures and coughing were observed 
after challenge. Pathology examinations including gross 
lung lesion scores, histopathologic lung lesion scores and 
immunohistochemistry (IHC) staining were performed. 
 
Results and Discussion 
 In the first experiment, pigs were not protected by 
IN/IN administration of RP against IAV challenge. Virus 
titers and pneumonia were not significantly reduced in the 
RP IN/IN administered group compared to the control group 
(Figure 1A). In the second experiment, in IN/IM or one dose 
IM administered pigs, from no more than two pigs at 2 DPC 
and 3 DPC, and no pigs at 3 DPC to 5DPC could virus be 
obtained. Live virus was detected in all five pigs from one 
dose RP IN group and the sham vaccinated group. We also 
found that one dose IM and combination of IN/IM 
vaccination with HA RP significantly reduced pneumonia 
lesions compared with sham vaccinated pigs (Figure 1B). 
Future study will evaluate whether IN/IM administration of 
RP will protect pigs against virus challenge, with the 
existence of IAV maternal antibodies in pigs.
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Table 1. Experiment 1 animal study protocol.  
Group name 
Pig 
numbers 
Day 0 prime 
vaccination 
Day 21 boost 
vaccination 
Day 42 challenge 
Day 47 
necropsy 
pigs 
Sham 5 IM Placebo IM placebo pH1N1 IAV 5 
IN/IN 5 IN RP IN RP pH1N1 IAV 5 
IM/IM 5 IM RP IM RP pH1N1 IAV 5 
 
Table 2. Experiment 2 animal study protocol. Brackets indicate the use of placebo instead of RP vaccine in the specific route.  
Group name 
Pig 
numbers 
Day 0 prime 
vaccination 
Day 21 boost 
vaccination 
Day 42 
challenge 
Day 47 
necropsy pigs 
IN/(IM) 5 IN RP IM placebo pH1N1 IAV 5 
IM/IM 5 IM RP IM RP pH1N1 IAV 5 
IN/IM 5 IN RP IM RP pH1N1 IAV 5 
(IN)/IM 5 IN placebo IM RP pH1N1 IAV 5 
(IM)/(IM) 5 IM placebo IM placebo pH1N1 IAV 5 
 
Figure 1. Mean of gross lung lesion scores of each group. Volumes represent mean of lung scores with standard errors and same 
lowercase character mean no statistically significant difference. (A) Experiment 1, there was no significant difference between 
sham and IN/IN group, but IM/IM group was significantly lower than sham and IN/IN group. (B) Experiment 2, significant 
difference was observed between IN/(IM), (IM)/IM groups and other three groups.   
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Experiment 1 : mean of gross lung lesion 
scores 
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Experiment 2: mean of gross lung lesion scores 
